Background
==========

The majority of microbial pathogens enter their hosts through a mucosal site; hence, effective vaccines should elicit immune responses at the site of infection \[[@B1],[@B2]\]. Ideally, vaccines against pathogens such as severe acute respiratory syndrome-associated coronavirus (SARS-CoV) which infects the airways should elicit immune responses in the mucosa of the respiratory tract \[[@B3]\]. Although mucosal application of vaccines is attractive for many reasons, only few mucosal vaccines \[most of them are given by the oral route and only one intranasal (i.n.) live-attenuated influenza vaccine\] have been approved for use in humans. Because oral administration of vaccines has been proven difficult for inducing immune responses in the respiratory tract \[[@B2]\], i.n. delivery of vaccines has been selected as an attractive alternative to injection. While i.n. vaccination elicits strong local and systemic immune responses, concerns about its safety have been raised following reports of unacceptable neurological side-effects associated with retrograde transport of antigens or adjuvants through the olfactory epithelium \[[@B4]-[@B7]\].

Replication-defective adenovirus (rADV) vectors are among the most attractive vectors for delivery of foreign antigens \[[@B8]-[@B20]\]. ADVs infect their host through the airway epithelium, and replicate in mucosal tissues of the respiratory tracts \[[@B21]\]. In a number of study models, mucosal vaccination with ADV has been shown to be effective at producing antibody (Ab) and T cell responses at the site of immunization \[[@B20],[@B22],[@B23]\]. However, when applied intranasally, ADV can enter the central nervous system (CNS) through binding to olfactory neurons \[[@B7],[@B24],[@B25]\]. The concerns call for alternative delivery routes.

The sublingual (s.l.) route has been extensively used for administration of immunotherapeutic allergens as a modality to induce suppression of type I allergic responses \[[@B26]-[@B29]\]. We have shown that s.l. administration of a prototype soluble protein antigen with cholera toxin (CT) adjuvant could induce Ab and cytotoxic T-lymphocyte (CTL) responses comparable to those seen after i.n. immunization \[[@B30]\]. In addition, s.l. administration of live influenza virus protected mice against influenza virus challenge without redirecting the immunizing virus to the CNS \[[@B31]\]. More recently, it has been shown that s.l. administration of rAd5 vectors encoding HIV proteins induced significant antigen-specific humoral \[[@B32]\] and cellular immune responses \[[@B33]\], indicating that s.l. route is suitable for rADV vaccines.

SARS-CoV is an enveloped virus containing a large single-strand RNA genome with positive orientation. The club-shaped peplomers radiating outwards from the viral envelope are composed of oligomeric forms of the \~180 kDa viral spike (S) glycoprotein. The S protein not only contains the receptor binding site and the putative fusion peptide, but it is also a major antigenic determinant of the virus and Abs targeting this protein neutralize the virus *in vitro* and *in vivo*\[[@B34]-[@B36]\].

In this study, we explored the suitability of the s.l. route for administering a replication-defective ADV encoding truncated S protein (rADV-S) lacking cytoplasmatic and transmembrane domains. The immune responses induced upon s.l. immunization with rADV-S were compared to those induced by i.n. and intramuscular (i.m.) routes. We found that s.l. delivery of rADV-S induced systemic and mucosal Abs, CD8^+^ T cell responses. Importantly, our immunization strategy generated SARS-CoV neutralizing antibodies (nAbs) at the titers that are presumably protective against the infection. In addition, we confirmed that s.l., in contrast to i.n. administration, did not redirect rADV to the olfactory bulb.

Results
=======

Characterization of rADV expressing SARS-CoV S protein
------------------------------------------------------

To confirm the expression of S protein *in vitro*, 293 cells were infected with rADV-S at 20 multiplicity of infection (MOI) for 48 hrs. Cell lysates and culture supernatants were collected and analyzed by Western blot. As shown in Figure [1](#F1){ref-type="fig"}B, a specific \~ 120 kDa protein band corresponding to the predicted size of the S protein, was observed in rADV-S infected 293 cells but not in rADV-EGFP infected cells. The portion of the S1 domain (S201-510) expressed in and purified from *E. coli* was used as coating antigen in ELISA. The purified protein was confirmed by Western blot using rabbit anti-SARS-S1 Ab (Figure [1](#F1){ref-type="fig"}C).

![**Construction of rADV vector expressing SARS-CoV S glycoprotein and expression of S proteins in 293 T cells and bacteria.** (**A**) The gene encoding codon-optimized SARS-S protein without helical regions, transmembrane domain and cytoplasmic domain was inserted into pShuttle vector to construct the rADV expressing the SARS-S protein. (**B**) 293 T cells were infected with rADV-S or rADV-EGFP and the S protein in the cell lysate was detected by Western blot. (**C**) DNA for SARS-S protein (amino acids 201--510) was inserted into pET15b vector to express recombinant S protein from *E. coli*. The protein was purified by His-tag affinity chromatography and detected by Western blot.](1743-422X-9-215-1){#F1}

S.l. Administration of rADV induced mucosal Ab responses
--------------------------------------------------------

To compare the immune responses induced by different delivery routes, we immunized s.l., i.n., or i.m. each group of BALB/c mice three times 14 days apart with either 2 × 10^7^ or 1 × 10^8^ plaque-forming unit (PFU) of rADV-S. Sera from the animals were collected 2 weeks after each immunization and tested for S protein-specific IgG by ELISA. IgG titers were detected as soon as 2 weeks after the first immunization regardless of delivery route. However, i.m. immunization induced the highest S protein-specific IgG titers in the sera as compared to i.n. and s.l. immunizations (Figure [2](#F2){ref-type="fig"}A). The peak of IgG titers was reached in all groups upon second immunization as third immunization did not significantly increase the IgG titers.

![**SARS-CoV S-specific humoral immune responses in the immunized mice.** Mice were immunized with rADV-S by s.l., i.n., or i.m. route. Sera were collected two weeks after each vaccination and BAL was collected two weeks after the last immunization. S-specific IgG titers in sera (**A**) and S-specific IgA titers in BAL (**B**) were determined by ELISA. The results are expressed as the means + SD. The data are representative of three separate experiments.](1743-422X-9-215-2){#F2}

Since SARS-CoV infects mucosa of the lungs, an effective vaccination strategy should induce specific immune response in the lungs, the site of infection. I.n. administration is well recognized for excellent induction of immune responses in mucosal compartments of the respiratory tract \[[@B37],[@B38]\]. We asked whether s.l. immunization with rADV-S induces antigen-specific Ab in the lungs. We examined the level of IgA specific for SARS-S protein in Bronchoalveolar lavages (BAL) of mice upon s.l. immunization. As shown in Figure [2](#F2){ref-type="fig"}B, significant level of IgA specific for SARS-S protein was observed in BAL of s.l. immunized mice 2 weeks after the third immunization. The IgA level is comparable to that seen in BAL of i.n. immunized mice.

S.l. Administration of rADV induced SARS-CoV nAb
------------------------------------------------

nAbs against the S protein are considered a surrogate of protection against infection with the SARS-CoV \[[@B39],[@B40]\]. We examined whether s.l. immunization with rADV-S induces nAbs. Groups of 6 mice each were immunized three times 2 weeks apart with rADV-S via either s.l., i.n., or i.m. route. Two weeks after the third immunization sera were collected and analyzed for SARS-CoV neutralization using microneutralization assay. As shown in Figure [3](#F3){ref-type="fig"}, all immunization routes induced significant levels of nAbs. The endpoint titers of nAbs are far above the titer of 1/35 that is considered to be protective in mice \[[@B36]\]. Thus, the results demonstrate that s.l. immunization with rADV-S induced high titer of nAbs against SARS-CoV infection, presumably protection against infection with SARS.

![**SARS-CoV neutralizing activity of Sera.** Mice were immunized three times with rADV-S 2 × 10^7^ PFU by s.l., i.n., or i.m. route. Sera were tested to measure the Abs that would neutralize the infectivity of 100 TCID~50~ of SARS-CoV in Vero cell monolayers. Neutralization titers were determined by the CPE of SARS-CoV on Vero cell. The dotted line indicates the limitation of detection. The results are expressed as the means + SD.](1743-422X-9-215-3){#F3}

S.l. Administration of rADV expressing SARS-CoV S induced virus-specific CD8^+^ T cell responses in the respiratory tract
-------------------------------------------------------------------------------------------------------------------------

It has been suggested that CD8^+^ T cell responses are important for clearance of other coronaviruses such as mouse hepatitis virus \[[@B41],[@B42]\]. Therefore, we examined whether the administration of rADV-S via s.l., i.n., or i.m. route induces CD8^+^ T cell responses in the lungs and spleens. Ten days after the third vaccination, antigen-specific CD8^+^ T cells binding to MHC I tetramers containing the H-2K^d^-restricted SARS-CoV S epitope~366-374~ (CYGVSATKL) \[[@B43]\] and producing intracellular IFN-γ after *in vitro* re-stimulation with CYGVSATKL peptide were determined. As shown in Figure [4](#F4){ref-type="fig"}A, i.n. and s.l. immunization routes induced significantly higher percentages of SARS S-specific CD8^+^ T cells in the lungs (6.7 and 6.4%, respectively) as compared to i.m route (3.2%). Similarly, i.n. and s.l. immunization routes induced significantly higher percentages of IFN-γ-producing CD8^+^ T cells in the lung (10.5 and 8.5%, respectively) in response to SARS S protein. As expected, i.n. and s.l. immunization routes induced lower percentages of SARS S-specific CD8^+^ T cell and IFN-γ-producing CD8^+^ T cell in the spleens (Figure [4](#F4){ref-type="fig"}B) as compared to that induced by i.m. immunization. The results clearly demonstrate that s.l. and i.n. administrations of rADV-S are equally efficient in induction of CD8^+^ T cell responses in the lungs.

![**Detection of S**~**366-374**~**epitope-specific and IFN-γ secreting CD8**^**+**^**T lymphocytes in the mice vaccinated with rADV-S.** Mice were immunized three times with rADV-S 1 × 10^8^ PFU by s.l., i.n., or i.m. route. Lung (**A**) and spleen (**B**) lymphocytes were harvested 10 days after the final immunization and were tested by flow cytometric analysis after staining with S~366-374~ tetramer, IFN-γ, CD8 and CD44.](1743-422X-9-215-4){#F4}

S.l. Administration of rADV did not redirect virus to olfactory bulb
--------------------------------------------------------------------

It has been reported that the i.n. administration of rADV resulted in virus migration to the olfactory bulb \[[@B7]\]. To investigate whether or not s.l. administration of rADV redirects the virus vector to the olfactory bulb, 1 × 10^8^ PFU of rADV were administered either intranasally or sublingually. Twenty-four hours later, the olfactory bulbs were collected and the presence of adenoviral DNA was determined by PCR. As shown in Table [1](#T1){ref-type="table"}, no adenoviral DNA was detected in olfactory bulbs of s.l. immunized mice. In contrast, adenoviral DNA was detected in olfactory bulbs of all 8 i.n. immunized mice. Viral DNA was detected in the lungs of all s.l. immunized mice, as was the case for mice immunized intranasally.

###### 

The distribution of rADV-EGFP in the lung and olfactory bulb of mice after i.n. or s.l. administration

   **Route**   **PCR positive in lung**^**a**^   **PCR positive in olfactory bulb**
  ----------- --------------------------------- ------------------------------------
       i.n.                  8/8                                8/8
       s.l.                  8/8                                0/8

^a^ BALB/c mice were immunized with rADV-EGFP by i.n. or s.l. injection and next day, the lung and olfactory bulb were removed from the immunized mice. DNA was purified from the lungs and olfactory bulbs by using DNeasy tissue kit. The results were determined by PCR as described in Materials and Methods.

Discussion
==========

In this study, we demonstrate that s.l. administration of the rADV-S induced SARS-CoV S-specific immune responses in mucosal and systemic compartments. The results are in the line of our previous studies and those of others indicating that s.l. immunization induced broad spectrum of specific immune responses \[[@B30],[@B31]\]. Indeed, s.l. immunization induced immune responses in respiratory \[[@B30]\] and vaginal tracts \[[@B44]-[@B46]\]. The former is not exceptional for our ADV encoding SARS-CoV since the rADV-S induced significant immune responses in respiratory tracts and systemic compartments. It is noteworthy that protein S specific IgA Ab response in BAL could be only induced when the animals were immunized either intranasally or sublingually. This characteristic of rADV is particularly important for the development of mucosal vaccines against respiratory pathogens. The levels of IgG and IgA induced in the blood upon s.l. immunization are comparable to those elicited by i.n. immunization which has been considered to be the best immunization route for induction of broad mucosal and systemic immune responses \[[@B30]\], indicating that s.l. immunization with rADV-S is an option for effective induction of systemic immunity. Importantly, s.l. immunization with rADV-S induced nAb at the level that is presumably protective against the challenge with live virus. It has been reported that nAbs targeting S protein play an important role in protection against SARS-CoV infection \[[@B47]\]. We found all immunization routes including s.l. immunization induced nAb titers above 1/35 that is considered to be protective in mice \[[@B36]\], indicating that our designed rADV-S is suitable for induction of protective immunity to wild type SARS-CoV.

In consideration of the emergence of nAb escape mutant and clinical observations in SARS patients who showed a decrease of CD8^+^ memory T cells \[[@B48]\], it is desirable to develop a SARS vaccine which can induce both humoral and cellular immune responses. Here, we showed that s.l. and i.n. immunizations of rADV-S induced higher levels of SARS-CoV S-specific CD8 T cell responses in the lung than that of i.m. immunization. The findings are in consistence with other studies showing that rADV expressing S protein could induce cellular immune responses \[[@B49],[@B50]\]. Thus our immunization strategy involving rADV-S delivery through s.l. mucosa offers readily a tool to combat potential newly emerging SARS mutant.

There is a concern about pre-existing Abs against adenovirus in the human population that may prevent the immunization with rADV vector \[[@B51]\]. We showed that S-specific IgG Ab responses induced after the first immunization could be further boosted by a second administration of the rADV vector vaccine, but the third round of vaccination failed to induce an increase in the serum Ab levels. It is likely that the IgG titers induced after the second immunization already reached their maximum and could not be further boosted. Similarly, higher levels of serum specific IgG induced upon first i.m. immunization as compared to that induced by i.n. or s.l. immunization could not be further boosted.

It has been shown that i.n. but not i.m. immunization with rADV encoding SARS S and nucleocapsid (N) proteins significantly reduced SARS-CoV titer in the lungs after challenge, suggesting that i.n. immunization induced protective immune responses in the lungs, the site of infection \[[@B3]\]. Although i.n. delivery of vaccines induces effectively protective immunity, several observations raised safety concerns for its use in humans \[[@B7],[@B25]\]. I.n. delivery of protein antigen together with CT as an adjuvant redirects antigen to CNS \[[@B31]\] and i.n. delivery of inactivated influenza vaccine caused Bell's palsy in some human recipients \[[@B52]\]. In addition, i.n. delivery of rADV redirects the virus to the olfactory bulb via retrograde transport. These concerns call for an alternative immunization route for safe and effective induction of mucosal immune responses. Oral vaccination has been known to induce mucosal immunity and is safer than i.n. immunization, however degradation of the vaccine by the acidic pH and proteolytic enzymes in the gastrointestinal tract complicate the oral vaccination \[[@B2]\]. We chosen s.l. route as it was used for allergen immunotherapy \[[@B26]\] and was shown to be safe.

The s.l. delivery of rAd vectors expressing HIV-Gag was shown to induce Ag-specific CTL responses in mice even with preexisting immunity to Ad5 \[[@B33]\]. In addition, a recent study demonstrated that s.l. administration of rAd5 vector expressing HIV-Env was effective in penetrating the sublingual epithelium and induced Ag-specific mucosal Ab responses without adjuvant \[[@B32]\].

The present study describes a finding that s.l. delivery of rADV-S could induce systemic IgG and airway IgA SARS-CoV nAb as well as CD8^+^ T cell responses in mice. In contrary to i.n. administration, s.l. delivery of rADV does not redirect the rADV to the CNS. Our data indicated that s.l. administration could be an alternative mucosal route for safe and effective vaccination with rADV.

Conclusions
===========

The s.l. delivery of rADV-S induced humoral and cellular immune responses without accumulation of rADV in olfactory bulb. Importantly, these immune responses are comparable with those induced by i.n. administration. Thus, our study suggests that s.l. immunization with rADV-S offers a novel safe and effective vaccination strategy to combat SARS-CoV.

Materials and methods
=====================

Construction of rADV expressing SARS-CoV S protein
--------------------------------------------------

The ectodomain (amino acids 14--891) of the SARS-CoV S protein lacking the transmembrane domain and the cytoplasmatic tail was codon-optimized for high-level expression in mammalian cells and synthesized by GenScript Co. (Piscataway, NJ). The natural signal sequence was replaced by that of tissue plasminogen activator. Helical regions together with transmembrane domain and cytoplasmic domain were deleted as previously reported \[[@B39]\]. Briefly, rADV expressing SARS-CoV S gene was generated using the AdEasy Vector System according to the manufacturer's instructions (Stratagene, La Jolla, CA). To inhibit the expression of SARS-CoV S gene during the course of ADV production, a tetracycline-regulated expression system was adopted. Two tetracycline operator sequences derived from pcDNA4/TO (Invitrogen, Carlsbad, CA) have been inserted between the TATA box of the CMV promoter of pShuttle-CMV (Stratagene), resulting in pShuttle-TetO2. After subcloning of SARS-CoV S gene into pShuttle-TetO2 (Figure [1](#F1){ref-type="fig"}A), this was co-transformed with adenoviral backbone vector, pAdEasy, into *Escherichia coli* (*E. coli*) BJ5183 by electroporation to achieve homologous recombination. The resulting construct was transfected into T-Rex-293 cells (Invitrogen) by the calcium phosphate co-precipitation method. T-Rex-293 cells were maintained according to the manual. Recombinant ADV was isolated from a single plaque, expanded in T-Rex-293 cells, and purified by double cesium chloride ultracentrifugation. The purified viruses were extensively dialyzed against 10 mM Tris, 5% sucrose, 2 mM MgCl~2~ and stored in aliquots at −80°C until use. Titers of ADV were determined by Tissue culture infectious dose 50 (TCID~50~) and by plaque assays in T-Rex-293 cells.

Western blot analysis
---------------------

The rADV-S infected 293 T cell lysate was separated by 10% SDS-PAGE. After electrophoretic transfer to nitrocellulose membrane (Schleicher & Schuell, Germany), the membrane was blocked with Tris-buffered saline (TBS) containing 5% skim milk and incubated with rabbit anti-SARS-S1 Ab (kindly provided by Chiron/Novartis, Italy) at a 1:3,000 dilution in TBST (TBS and 0.05% Tween 20) containing 5% skim milk for 1 hr at room temperature. After washing with TBST, the membranes were probed with incubation with goat-anti-rabbit Immunoglobulin G (IgG) conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:3,000 dilution in TBST containing 5% skim milk and detected by chromogenic substrate (ECL kit; Amersham Pharmacia Biotech Inc., Piscataway, NJ).

Immunizations
-------------

The immunization schedule is summarized in Table [2](#T2){ref-type="table"}. Six-week-old female BALB/c mice (Orient, Korea) were maintained under specific pathogen-free conditions and all studies were approved by Institutional Animal Care and Use Committee (IACUC) at the International Vaccine Institute (2010--015). Mice were immunized i.m. with rADV-S 2 × 10^7^ PFU in 100 μl phosphate-buffered saline (PBS), i.n. or s.l. with rADV-S 2 × 10^7^ or 1 × 10^8^ PFU in 20 μl of PBS \[[@B30]\]. In each experiment, mice (n = 6) were immunized three times at 2-week intervals. Control mice were immunized intramuscularly with rADV-Mock (2 × 10^7^ PFU/mouse).

###### 

Immunization schedule

  **Group**   **1st (day 0)**    **2nd (day 14)**   **3rd (day 28)**   **Routes**^**a**^
  ----------- ------------------ ------------------ ------------------ -------------------
  1           rADV-Mock          rADV-Mock          rADV-Mock          i.m.
  2           rADV-S 2 × 10^7^   rADV-S 2 × 10^7^   rADV-S 2 × 10^7^   i.m.
  3           rADV-S 2 × 10^7^   rADV-S 2 × 10^7^   rADV-S 2 × 10^7^   i.n.
  4           rADV-S 1 × 10^8^   rADV-S 1 × 10^8^   rADV-S 1 × 10^8^   i.n.
  5           rADV-S 2 × 10^7^   rADV-S 2 × 10^7^   rADV-S 2 × 10^7^   s.l.
  6           rADV-S 1 × 10^8^   rADV-S 1 × 10^8^   rADV-S 1 × 10^8^   s.l.

^a^ Groups of six BALB/c mice were immunized s.l., i.n., or i.m. with rADV-S three times at 2-week intervals.

Sample collection
-----------------

Blood was collected from the retro-orbital plexus 2 weeks after each immunization, followed by incubation at room temperature for 30 min. Sera were obtained from the blood by centrifugation for 10 min at 13,000 rpm. Bronchoalveolar lavages (BAL) were collected on day 43 under anesthesia by repeated intra-tracheal flushing and aspiration of 500 μl of PBS per lung of mouse.

ELISA
-----

SARS-CoV S-specific Ab titers were determined by enzyme-linked immunosorbent assay (ELISA). Truncated SARS-CoV S protein (amino acids 201--510) was used as antigen. The gene encoding truncated S (residues 201--510) was inserted into pET15b vector (Novagen, Madison, WI). The protein was expressed in *E. coli* BL21 (DE3) (Novagen) and purified by Talon metal affinity column (Clontech, Palo Alto, CA). To measure the Ab responses, either the purified SARS-CoV S1 protein (amino acids 201--510) or a truncated S protein with a transmembrane deletion (Protein sciences corporation, Meriden, CT) was diluted to 2 μg/ml with 50 mM Sodiumbicarbonate buffer (pH 9.6). Microtiter plates (Nunc, Denmark) were pre-coated with 100 μl of the diluted protein per well and incubated overnight at 4°C. The plates were washed with PBS and blocked with 5% skim milk in PBS for 1 hr at room temperature. 100 μl of 2-fold serial dilution of samples in blocking buffer were added to each well and incubated for 1 hr at 37°C, followed by the addition of 1:3,000 diluted horseradish peroxidase-conjugated goat anti-mouse IgG or IgA (Santa Cruz biotechnology). After incubation for 1 hr at room temperature, 100 μl of peroxidase substrate tetramethylbenzidine (TMB) (Millipore, Bedford, MA) was added to each well. The reaction was stopped by adding 0.5 N HCl. The absorbance at wavelength 450 nm was recorded by a microplate reader (Molecular Devices, Sunnyvale, CA). The endpoint titer was determined by O.D. cut-off values of 0.2.

Virus neutralization assay
--------------------------

The neutralization assay using active SARS-CoV was carried out in a biosafety level 3 laboratory. Virus microneutralization assay was performed as described previously \[[@B35]\]. Briefly, two-fold serial dilutions of heat-inactivated (30 min., 56°C) sera were tested against 100 TCID~50~ of SARS-CoV in Vero cell monolayers. The cytopathic effect (CPE) of SARS-CoV on Vero cell monolayers was read on day 4 and the neutralization titer was calculated by the Spearman/Karber formula \[[@B53]\].

Flow cytometry analyses
-----------------------

For MHC class I tetramer staining, recombinant MHC class I Kd/SARS-CoV complexes were generated using the procedure described by D. Busch and E. Pamer (Yale University, New Haven, CT) \[[@B54]\]. Briefly, H-2K^d^ heavy chain-biotinylation site fusion and human β2-microglobulin were expressed in *E. coli*, purified from inclusion bodies, solubilized, and refolded in the presence of corresponding CYGVSATKL (S366-374) SARS-CoV peptide, a major CD8^+^ T cell epitope \[[@B43]\]. Complexes were then enzymatically biotinylated by BirA ligase (Avidity, Denver, CO) and were purified by Superdex-75 gel filtration and Mono-Q anion exchange chromatography (Amersham Pharmacia Biotech Inc.). The biotinylated monomer complexes were tetramerized with PE-labeled streptavidin (Molecular Probes, Eugene, OR). Tetramers were stored at 5 mg/ml in PBS (pH 8.0) containing 0.02% sodium azide, 1 μg/ml pepstatin, 1 μg/ml leupeptin, and 0.5 mM EDTA at 4°C. The lungs were perfused with 5 ml of PBS containing 10 U/ml heparin (Sigma-Aldrich) through the right ventricle using a syringe fitted with 25-gauge needle. The lungs were then removed and placed into RPMI medium supplemented with glutamine, gentamicin, penicillin G, and 10% fetal bovine serum (FBS) (HyClone, Logan, UT). The tissues were then processed through a steel screen to obtain single cell suspension, and particulate matter was removed by passing through 70 μm Falcon cell strainer (BD Labware). Freshly explanted lung cells were then purified by Percoll density gradient centrifugation. Spleen cells from immunized mice were resuspended in complete IMDM at a concentration of 1 × 10^7^ cells/ml. A total of 100 μl of these cells (1 × 10^6^ cells) were stained for CD8 (clone 53--6.7), CD44 (clone IM7), and Kd/SARS-CoV tetramer and samples were acquired on FACSCalibur (BD Biosciences, San Jose, CA). For intracellular staining, the cells were first stained for CD8 and CD44, washed, fixed and permeabilized with FACS buffer containing 0.5% saponin (Sigma-Aldrich). Then, the cells were stained with PE-conjugated anti-IFN-γ (XMG1.2) (eBioscience, Inc., San Diego, CA) or its control isotype Ab (rat IgG1) (eBioscience). Gates were set on lymphocytes by forward and side scatter profiles, and the data were analyzed using WinMDI version 2.9 software (The Scripps Research Institute, La Jolla, CA).

Detection of DNA in tissues
---------------------------

Mice were administered either i.n. or s.l. with 1 × 10^8^ PFU of rADV-EGFP in 20 μl PBS. The olfactory bulbs and lungs were removed from the mice 24 hrs after the administration of rADV-EGFP. DNA was isolated using the DNeasy Tissue Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol.

The EGFP gene was amplified by polymerase chain reaction (PCR) using a forward primer (5'-CCGGGGATCCGGTGAGCAAGGGCGAGGAG-3') and a reverse primer (5'-CCGGAAGCTTTCTTGTACAGCTCGTCCAT-3'). PCR was performed under the following conditions: 5 min at 95°C denaturation, 30 cycles: 30s at 95°C, 30s at 55°C, 1 min at 72°C; 10 min at 72°C additional extension. The PCR products were loaded on 1% agarose gel.

Statistical analysis
--------------------

Statistical differences between experimental and control groups were determined by unpaired Student's *t* test. A *P* value of less than 0.05 was considered significant.
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